Findings from a large “real-world” study show the multimodal minimally invasive glaucoma surgery (MIGS) device, Hydrus Microstent (Ivantis) safely and effectively treats a wide variety of glaucoma types, providing reductions in IOP and medication burden that are durable through at least three years, reports Ophthalmology Times.
Dr Jeffrey Whitman, ophthalmic surgeon and president of the Key-Whitman eye centre in Dallas, said the SPECTRUM registry was developed to collect outcomes data for patients treated with the MIGS device either in combination with cataract surgery or as a standalone procedure. 2,500 eyes globally were enrolled through 2018.
“It is important to state what is meant by ‘real-world’. The SPECTRUM registry includes all-comers,” he told the American Society for Cataract and Refractive Surgery (ASCRS) in May. “It is a global, multicenter registry including data from 51 centers in 17 countries, all outside of the US. The large population of enrolled eyes also represents the full spectrum of glaucoma severity, from mild through advanced, including eyes with glaucoma refractory to prior incisional/filtration surgery,” he added.
Analyses of change from baseline IOP showed statistically significant reductions at 12 months (-3.6 mmHg), 24 months (-3.9 mmHg), and 36 months (-4.2 mmHg). There was also a statistically significant and consistent reduction in medication at all follow-up intervals showing patients on average eliminated use of one medication.
“At 12 months, 58% of eyes were medication free, and even at 3 years, more than 42% of eyes were using no ocular hypotensive medications,” Dr Whitman said.
